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EditorialRegulation of the expression of the hepatocellular sulfate–oxalate
exchanger SAT-1 (SLC26A1) by glyoxylate: A metabolic link
between liver and kidney?q
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See Article, pages 513–520The liver and kidney are the key organs in detoxiﬁcation of
endogenous and exogenous substances from the body. Detoxiﬁ-
cation of lipophilic endogenous substances and lipophilic xenobi-
otics involves biotransformation. This process starts with
functionalization of the molecule, often by a member of the fam-
ily of cytochrome P450 enzymes, followed by conjugation with a
hydrophilic molecule, e.g. by glucuronidation or sulfonation. In
the case of sulfonation, the sulfate donor for sulfotransferases is
30-phosphoadenosine 50-phosphosulfate, which is synthesized
from sulfate and ATP [9]. Hence, ongoing sulfonation requires
supply of sulfate as inorganic anion. Furthermore, sulfation is
an important post-translational modiﬁcation of proteins. In the
body, sulfate transport is mediated by two different types of
transporters: secondary active sodium-dependent transporters
and sodium-independent sulfate/anion exchangers [17]. The role
of sulfate transporters in detoxiﬁcation is highlighted by the
observation that mice with a disrupted gene for the sodium-
dependent sulfate transporter NaS1 (Slc13a1) or the sodium-
independent sulfate anion transporter Sat-1 (Slc26a1) display
hypersulfaturia, hyposulfatemia and increased sensitivity to acet-
aminophen induced liver injury [5,14], while the role of sulfate
transporters in post-translational protein modiﬁcation is evi-
denced by lethal and nonlethal disorders in patients with muta-
tions in sulfate transporters [10,12,20] and an impaired intestinal
barrier function in mice with a disrupted gene for NaS1 [4].
Sat1 is the founding member of the SLC26A family, was cloned
from rat liver [1] and is localized to the basolateral plasma mem-
brane of hepatocytes and kidney proximal tubular cells, respec-
tively [8,19]. It acts as an anion exchanger and transports, in
addition to sulfate, also chloride, bicarbonate, and oxalate in an
electroneutral manner [1,11]. The oxalate pool is fed by dietary
oxalate and as such absorbed to a minor extent in the intestine
[6]. More important is endogenous oxalate, which is a metabolic
end product, mainly derived from ascorbic acid and glycine [6].
Elimination of oxalate from the body is complex, but seems toJournal of Hepatology 20
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by the gut. The role of the gut in oxalate homeostasis gains
importance with progression of renal failure [3] and is high-
lighted by the observation that patients with a short bowel have
a considerable risk of developing calcium oxalate renal stones
[18]. Urolithiasis is also observed in mice with a disrupted Sat1
gene [5]. Therefore, Sat1 may not only be an important trans-
porter involved in sulfate homeostasis but also plays a critical
role in the proper excretion of oxalate from the body. Sat-1,
therefore, seems to play a broad role in detoxiﬁcation. Sulfate
homeostasis is predominantly, if not exclusively, regulated via
renal elimination [16], which also applies to oxalate [15].
It is evident from these physiologic and pathophysiologic
aspects that understanding the mechanisms of regulation of the
transporters involved in sulfate and oxalate homeostasis is clini-
cally highly relevant. Studies of the genes for sulfate transporters
revealed the presence of response elements for the thyroid hor-
mone T3 in the promoters of human and mouse Sat1 and NaS1,
but only the mouse promoter can be activated by T3 [12]. In addi-
tion, vitamin D and glucocorticoid response elements are present
in the promoter ofmouseNaS1 [12]. Very interestingly, the human
NaS1 promoter can be transactivated by 3-methylcholantrene,
which further supports the concept of an important role of sulfate
transporters in detoxiﬁcation [12]. In addition, mouse NaS1 is reg-
ulated by the farnesoid X receptor a (FXRa). Interestingly, the IR-1
element responsible for this regulation is located in intron 2 of
mouse NaS1 [13]. The physiologic relevance of this ﬁnding is illus-
trated by the observation that mice with a disrupted gene of FXRa
displayhypersulfaturia concomitantwith reducedmRNA levels for
Sat1 in the intestine and kidney. Interestingly, serum sulfate levels
were not statistically different between wild type and knock out
animals [13], whilemice lacking the vitamin D receptor have both,
hypersulfaturia and hyposulfatemia [2].
In this issue of the Journal of Hepatology, a study identiﬁes
glyoxylate as a substrate of Sat-1 and demonstrates a role of gly-
oxylate in the regulation of Sat-1 expression [21]. To demonstrate
Sat-1 mediated glyoxylate transport the authors expressed rat
Sat-1 in Xenopus laevis oocytes and performed uptake as well as
efﬂux experiments of radioactively labelled sulfate and oxalate,
which were combined with inhibition and trans-stimulation
experiments. Regulation of SAT-1 was studied in the human11 vol. 54 j 406–407
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hepatoma cell line HepG2 cultured in the presence of various
SAT-1 substrates at the mRNA and protein level. While sulfate
did not affect the expression of the three SAT-1 splice variants,
glyoxylate up-regulated all three splice variants markedly, while
oxalate only up-regulated splice variants 1 and 3. Glyoxylate lead
to a marked increase of SAT-1 protein expression in HepG2 cells
in conjunction with an up-regulation of sulfate uptake into
HepG2 cells. Taken together, the data clearly show that in the
model human hepatocyte cell line HepG2, the expression of
SAT-1 is controlled by intracellular glyoxylate levels.
Endogenous oxalate is primarily produced in the liver and, in
addition, in erythrocytes [15]. The metabolic precursor for oxa-
late is glyoxylate, which by itself is a metabolic intermediate
from various substances, such as hydroxyproline or glycolate. In
the liver, glyoxylate concentration in hepatocytes is kept low
by alanine–glyoxylate aminotransferase, which is located in per-
oxisomes. This enzyme depends on vitamin B6 for full activity
and converts glyoxylate into glycine [15]. In patients with muta-
tions in the gene coding for alanine–glyoxylate aminotransferase,
glyoxylate concentration in hepatocytes raises and consequently,
glyoxylate is converted into oxalate, excreted from hepatocytes
into blood and eliminated via the kidney where it leads to hyper-
oxaluria [15,22]. Such patients with primary hyperoxaluria type 1
develop kidney disease, i.e. nephrolithiasis. Oxalate has a very
limited solubility. It may not only be toxic to kidney cells [7]
but potentially also to hepatocytes. Consequently, an urgent need
may exist for hepatocytes to efﬁciently dispose of the excess of
oxalate formed as a consequence of primary hyperoxaluria type
I. The authors of the present study have observed that glyoxylate,
the direct metabolic precursor of oxalate, up-regulates the
expression of the oxalate efﬂux transporter SAT-1 in the human
liver cell line HepG2 [21]. It is therefore conceivable that the
same regulation occurs in vivo in hepatocytes and that SAT-1 pro-
tein and function are up-regulated in patients suffering from pri-
mary hyperoxaluria type I. This hypothesis is supported by the
observation that patients suffering from primary hyperoxaluria
type I do not present with overt liver disease.
Theworkof Schnedler et al. has addedanadditional pieceof evi-
dence that SAT-1,whichwas originally identiﬁed as a sulfate trans-
porter subject to inhibition by oxalate and 4,40-diisothiocyano-
2,20-disulfonic acid stilbene, plays an important role in detoxiﬁca-
tion. Based on its functional properties, Sat-1 was proposed to
reside in the canalicular plasma membrane of rat hepatocytes
[1], but was subsequently immunologically localized to the baso-
lateral plasma membrane of hepatocytes [19]. There, it mediates
the uptake of sulfate, a key constituent of drug metabolism in
exchange for oxalate, a metabolic end product destined for renal
elimination. Schnedler and co-workers now identiﬁed a novel
mechanism for the regulation of SAT-1 expression by glyoxylate,
a metabolic precursor of oxalate. Consequently, SAT-1 has now
moved into the spotlight as an additional element contributing to
hyperoxaluria in patients with an inherited defect of glyoxylate
metabolism. It will be interesting to see, whether SAT-1 is up-reg-
ulated in liver biopsies obtained frompatients needing a combined
liver and kidney transplant due to hyperoxaluria type I. Further-
more, the elucidation of the molecular mechanisms of the regula-
tion of Sat-1 expression will certainly help to better understand
the interplay of SAT-1 with phase II enzymes during drugmetabo-
lism. Itmight also shed light on the potential involvement of SAT-1
in the hepatic metabolism of toxins, such as for example after
ethylene glycol intoxication,which is associatedwith renal failure.
todeFinally, while a considerable amount of knowledge aboutJournal of Hepatology 201hepatocellular sulfate uptake has been worked out both at the
functional andmolecular level, themolecular identity of the cana-
licular sulfate–bicarbonate exchanger releasing sulfate into pri-
mary bile remains elusive and awaits identiﬁcation.Conﬂict of interest
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